Valuation : Ionis Pharmaceuticals, Inc.

Market Cap 10.19B 8.79B 8.28B 7.55B 14.11B 963B 14.21B 98.06B 38.06B 492B 38.27B 37.44B 1,617B P/E 2026 *
-16.8x
P/E 2027 * -32.4x
Enterprise Value 10.09B 8.7B 8.2B 7.47B 13.96B 953B 14.07B 97.07B 37.67B 487B 37.89B 37.06B 1,601B EV / Sales 2026 *
11x
EV / Sales 2027 * 7.31x
Free-Float
99.05%
Yield 2026 *
-
Yield 2027 * -
1 day+2.42%
1 week-3.20%
Current month+1.61%
1 month+18.47%
3 months-15.95%
6 months-25.17%
Current year-22.48%
1 week 59.7
Extreme 59.7
61.77
1 month 53.58
Extreme 53.58
64.19
Current year 50
Extreme 50.005
86.74
1 year 50
Extreme 50.005
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 01/07/2012
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/05/2000
Director TitleAgeSince
Director/Board Member 64 13/12/2005
Director/Board Member 73 01/05/2002
Director/Board Member 64 25/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
7/31/26 A Buy

Director

5,000 0.0030%
7/15/26 A Free

Director

3,399 0.0021%
7/15/26 A Free

Director

3,399 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
+2.42%-3.20%+6.68%+51.43% 9.95B
+0.97%-0.75%+3.51%+18.46% 49.74B
-0.30%-2.88%+429.29%+496.95% 44.98B
+2.13%+0.89%+43.59%+17.61% 42.52B
+0.87%-3.73%+8.96%+73.17% 40.78B
-0.90%-3.67%+14.26%+48.44% 32.89B
+2.71%+6.82% - - 17.09B
+1.68%-4.20%+25.28%+116.83% 16.28B
+1.70%-0.05%+18.53%+28.50% 14.4B
+3.34%-1.13%+80.94%+39.19% 13.48B
Average +1.46%-1.46%+70.12%+98.95% 28.21B
Weighted average by Cap. +1.06%-1.83%+90.59%+120.56%

Financials

2026 *2027 *
Net sales 913M 788M 742M 676M 1.26B 86.28B 1.27B 8.79B 3.41B 44.11B 3.43B 3.35B 145B 1.4B 1.21B 1.14B 1.04B 1.94B 132B 1.95B 13.49B 5.23B 67.71B 5.26B 5.15B 222B
Net income -602M -520M -490M -446M -834M -56.91B -840M -5.8B -2.25B -29.1B -2.26B -2.21B -95.58B -326M -281M -265M -241M -451M -30.78B -454M -3.14B -1.22B -15.74B -1.22B -1.2B -51.7B
Net Debt -103M -88.83M -83.68M -76.24M -143M -9.73B -144M -991M -384M -4.97B -387M -378M -16.34B 57.45M 49.57M 46.69M 42.54M 79.52M 5.43B 80.11M 553M 215M 2.77B 216M 211M 9.12B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,480
Date Price Change Volume
02/09/26 $61.33 +2.42% 1,845,866
01/09/26 $59.88 -0.80% 1,872,594
31/08/26 $60.36 -1.13% 2,017,160
28/08/26 $61.05 -2.21% 1,850,852
27/08/26 $62.43 -1.47% 1,625,581
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
61.33USD
Average target price
88.00USD
Spread / Average Target
+43.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock